The company, Accelerated Evolution Biotechnologies Ltd. (AEBi), has described its treatment, MuTaTo, as comparable to a cancer antibiotic that uses a multipronged approach similar to the treatment given to HIV patients. The Israeli team told The Jerusalem Post that this treatment relies on a combination of several peptides for each cancer cell, reportedly eliminating the chances of evasion through mutation.
“We believe we will offer in a year’s time a complete cure for cancer,” Dan Aridor, of AEBi, told the news outlet.
The company’s CEO, Dr. Ilan Morad, said MuTaTo also works to target cancer stem cells, eliminating the chances of recurrence, with Aridor claiming that it will be effective from “Day 1” and cause “no or minimal side effects at a much lower cost than most other treatments.”
Morad said the company’s initial efforts involved attempting to find “individual novel peptides for specific cancers.” But then he and colleague Dr. Hanan Itzhaki decided to go for broke. He explained that most anti-cancer drugs attack a specific target on or in the cancer cell, but they often trigger a mutation that makes the drug ineffective. But MuTato, as the Jerusalem Post notes, uses “a combination of several cancer-targeting peptides for each cancer cell at the same time, combined with a strong peptide toxin that would kill cancer cells specifically.”
Thank you Pesky Truth Blog